🔎 Trials Near Me

Beranda › Kanker Ovarium › Tennessee

Uji klinis Kanker Ovarium di Tennessee

55 studi untuk Kanker Ovarium mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Vanderbilt University/Ingram Cancer Center, Nashville
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
  • Regional Cancer Center at Johnson City Medical Center, Johnson City
  • Ballad Health Cancer Care - Kingsport, Kingsport
  • dan 3 lainnya
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT05564377

A Study of PHST001 in Advanced Solid Tumors

  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06840886

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Tennessee Oncology, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology PLLC, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Sarah Cannon Research Institute (SCRI), Nashville
Menerima pesertaFase 1
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06586957

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06799065

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05877599

DESTINY-PANTUMOUR04

  • Research Site, Nashville
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04981119

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Nashville
Menerima pesertaFase 2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • University Of Tennessee Medical Center /ID# 278225, Knoxville
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 22 Sep 2026 · NCT07059845

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Sarah Cannon Research Institue, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Sarah Cannon - Tennessee Oncology, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • West Cancer Center and Research Institute ( Site 0013), Germantown
  • University of Tennessee Medical Center ( Site 0087), Knoxville
  • Henry-Joyce Cancer Clinic ( Site 0011), Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 17 Sep 2026 · NCT07318558

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Sarah Cannon Nashville, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Erlanger Health, Inc., Chattanooga
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 15 Sep 2026 · NCT07214779

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 3 Sep 2026 · NCT07755436

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 1
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04895709

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Vanderbilt-Ingram Cancer Center at Franklin, Franklin
  • Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • dan 1 lainnya
Menerima peserta
Usia 35 hingga 50 · Wanita · Diperbarui 7 Agu 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Vanderbilt-Ingram Cancer Center at Franklin, Franklin
  • Vanderbilt-Ingram Cancer Center Cool Springs, Franklin
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06580314

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Erlanger Health, Inc, Chattanooga
  • The West Clinic, Germantown
  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville
  • Tennessee Oncology, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Tennessee Oncology, PLLC, Chattanooga
  • SCRI Oncology Partners, Nashville
  • Vanderbilt Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • SCRI - TriStar Medical Group Children's Specialists, Nashville
  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

  • Investigative Site #102, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jul 2026 · NCT06545942

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • SCRI Oncology Partners, Nashville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06695845

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.